Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Grassley backs FDA “whistleblower”

Executive Summary

Senate Finance Committee Chairman Charles Grassley (R-Iowa) asks FDA in Nov. 29 letter to explain allegations that Office of Drug Safety Associate Director for Science David Graham, MD, will face compulsory reassignment or be fired for criticism of the agency at Vioxx hearing (1"The Pink Sheet" Nov. 22, 2004, p. 4). A Nov. 24 letter from Grassley calls for an HHS Office of Inspector General investigation of reports that two FDA managers sought to preemptively discredit Graham to a whistleblower protection organization. "It appears that these activities may have been coordinated by FDA management and may have involved the misuse of government resources," Grassley says...

You may also be interested in...

Crestor, Serevent Safety Issues Push Vioxx Out Of Spotlight In Senate Hearing

FDA's focus following the Senate Finance Committee hearing on the Vioxx withdrawal is on defending the safety of five other drugs challenged by one of its safety reviewers

Lauder Q2 Sales Pummeled By China Closures, US Skin-Care Slowdown

The Estee Lauder Companies, Inc. reported a 17% decline in fiscal 2023 second quarter sales due to pandemic-related closures in China as well as a slowdown in orders of US skin-care products. But the company says both its Chinese and US markets should be “growth drivers” in the second half of the year as markets open up and new innovations kick in.

Hyloris Partner Signs To Market Maxigesic IV In Central And Eastern Europe

Hyloris’ partner AFT has signed an exclusive licensing and distribution agreement with Salus Pharmaceuticals covering nine central and eastern European countries. Meanwhile, Hyloris has also struck an in-licensing deal for a new blood phosphorus deficiency treatment. 


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts